Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $18.25.

Several equities analysts have recently issued reports on the stock. Benchmark reissued a “speculative buy” rating and set a $15.00 price target (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright decreased their target price on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. B. Riley Financial restated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Neutral Sentiment: Rosen Law Firm and Faruqi & Faruqi reminded investors who purchased Unicycive securities between December 29, 2025, and June 29, 2026, that they may seek appointment as lead plaintiff in the federal securities class action. These announcements do not represent a judgment against the company. Rosen law firm investor notice
• Negative Sentiment: The lawsuit-related notices allege that Unicycive told shareholders its oxylanthanum carbonate (OLC) application was progressing as planned without independently verifying whether its third-party manufacturer had corrected deficiencies cited in an earlier FDA rejection. The allegations raise concerns about disclosure practices and the regulatory prospects for the company’s lead drug candidate. UNCY shareholder alert
• Negative Sentiment: Robbins LLP, Kaplan Fox, Levi & Korsinsky, Bronstein Gewirtz & Grossman, and Glancy Prongay Wolke & Rotter issued similar reminders on October 5. The repeated publicity increases visibility around the allegations, which could pressure investor confidence and potentially expose Unicycive to litigation costs, damages, and management distraction. The complaints reportedly reference losses of approximately $3.01 per share during the class period. Robbins LLP UNCY stock drop notice

Unicycive Therapeutics Trading Up 1.0%

Shares of NASDAQ UNCY opened at $4.23 on Friday. The business has a 50 day simple moving average of $5.06 and a 200-day simple moving average of $6.21. Unicycive Therapeutics has a twelve month low of $3.93 and a twelve month high of $8.74. The company has a market capitalization of $117.83 million, a price-to-earnings ratio of -2.42 and a beta of 1.83.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.41. As a group, equities analysts predict that Unicycive Therapeutics will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in UNCY. Seven Fleet Capital Management LP grew its holdings in Unicycive Therapeutics by 85.6% during the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after acquiring an additional 47,700 shares during the period. Bank of New York Mellon Corp acquired a new stake in Unicycive Therapeutics in the 2nd quarter valued at about $248,000. Bank of America Corp DE boosted its holdings in Unicycive Therapeutics by 19,327.6% during the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after buying an additional 29,378 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics during the 1st quarter worth $161,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Unicycive Therapeutics in the 1st quarter valued at $940,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease. The company’s primary focus is hyperphosphatemia, a condition in which phosphate levels become abnormally high in patients with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.